Expression of Ezrin and its relationship with clinicopathological characteristics in breast cancer

Hui-ping YU,Xiang-shan FAN,Dong-sheng ZHANG,Fan-qing MENG,Qiang ZHOU,Hong-yan WU
DOI: https://doi.org/10.3969/j.issn.1673-5269.2008.19.001
2008-01-01
Abstract:Objective: To investigate the expression of Ezrin and its relationship with clinicopathological characteristics in breast cancer. Methods: By the tissue microarray technique and immunohistochemical method, expression of Ezrin, ER, PR, c-erbB-2, MMP-2 and MMP-9 was detected in 117 cases of invasive breast carcinoma and 41 cases of benign breast hyperplasia. Results: The subcellular distributions of Ezrin in benign and malignant mammary tiss ues were significantly different, P = 0.000. Ezrin staining in most (91.89%, 34/37) benign breast epithelium localized at the apical, and no cytoplasmic staining was observed, but in 76. 99%(87/ 113)of breast cancer cases, it localized in the cytoplasm and no apical staining was observed. In breast cancer cases, Ezrin expression in tumor cells was positively related with larger tumor size (P = 0.016), higher TNM stage (P = 0.002), lymph node metastases (P = 0.036), stronger expression of MMP-2 (P = 0.007), and MMP-9 (P = 0.002) in stromal cells. There were no further associations between Ezrin expression and any other clinico-pathological features. Conclusions: Subcellular distribution of Ezrin change obviously in benign and malignant lesions of breast, which is of aid in estimating the characteristics of breast lesions. The higher expression level of Ezrin in breast carcinoma suggests stronger ability of invasion and lymph node metastasis.
What problem does this paper attempt to address?